Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Chimeric Antigen Receptor (CAR) T-cell therapy, as an approved treatment option for patients with B cell malignancies, demonstrates that genetic modification of autologous immune cells is an effective anti-cancer regimen. Erythropoietin-producing Hepatocellular receptor tyrosine kinase class A2 (EphA2) is a tumour associated antigen expressed on a range of sarcomas, including paediatric osteosarcoma (OS) and Ewing sarcoma (ES). We tested human EphA2 directed CAR T cells for their capacity to target and kill human OS and ES tumour cells using in vitro and in vivo assays, demonstrating that EphA2 CAR T cells have potent anti-tumour efficacy in vitro and can eliminate established OS and ES tumours in vivo in a dose and delivery route dependent manner. Next, in an aggressive metastatic OS model we demonstrated that systemically infused EphA2 CAR T cells can traffic to and eradicate tumour deposits in murine livers and lungs. These results support further pre-clinical evaluation of EphA2 CAR T cells to inform the design of early phase clinical trial protocols to test the feasibility and safety of this immune cell therapy in paediatric bone sarcoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Zhang et al. conducted the third-generation CAR-T cells targeting B7-H3 and proved the killing effects for tumor cells in vitro and in vivo using the patientderived xenografts (PDXs) model of osteosarcoma [116–125].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [119]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“EphA2-CAR-T cells showed superior efficacy for liver and lung metastatic osteosarcoma cells when delivered systemically [119].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“in subcutaneous osteosarcoma mouse models, EphA2-CAR-T cells induced significant reduction or elimination of osteosarcoma and extended survival in a dose and delivery route-dependent manner”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207247 · Cited by 211
RetractedTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
THE EPHRINS AND EPH RECEPTORS IN NEURAL DEVELOPMENT
Flanagan, J. G., & Vanderhaeghen, P. (1998) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.21.1.309 · Cited by 1,080
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Self-citationWang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R., & Kinch, M. S. (2001) · PubMed · Cited by 463
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
Wykosky, J., & Debinski, W. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0244 · Cited by 300
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 276
Lindberg, R. A., & Hunter, T. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6316 · Cited by 257
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Besides, EphA2-CAR-T cells showed superior efficacy for liver and lung metastatic osteosarcoma cells when delivered systemically [119].”
BackgroundEph receptors and ephrins in cancer progression
Pasquale, E. B. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00634-x · Cited by 155
Lin, Q., Ba, T., Ho, J., Chen, D., Cheng, Y., Wang, L., Xu, G., Xu, L., Zhou, Y., Wei, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.694941 · Cited by 127
“org 5 redirected CAR T-cells against established lung metastasis animal model has demonstrated that the intravenously infused CAR T-cells could traffic into the lung tissue (17).”
BackgroundTumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 75
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis
Nirala, B. K., Yamamichi, T., Petrescu, D. I., Shafin, T. N., & Yustein, J. T. (2023) · Cancers · doi:10.3390/cancers15205108 · Cited by 57
“Systemic infusion of EphA2 CAR-T cells traffic to and eradicate tumor deposits in murine liver and lung metastases [192].”
Background
Metadata
- Authors
- Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B.
- Affiliations
- Children's Hospital at Westmead (AU)
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Kramer, Belinda
- Venue
- Cancer Gene Therapy
- Published
- 2020-09-01
- Volume
- 28
- Issue
- 3-4
- Pages
- 321-334
- ISSN
- 0929-1903 (ISSN-L)
- 1476-5500
- PMC
- PMC8057949
- OpenAlex
- W3081876782
- Cited by
- 51
- References
- 49
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 6 · 2021: 8
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cancer Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Institute NSW
- Kids' Cancer Project
- Australia and New Zealand Sarcoma Association
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- chimeric antigen receptor T cells, EphA2, pediatric bone tumors, osteosarcoma, Ewing sarcoma, CAR T-cell therapy, tumor-associated antigens, tumor cell killing, metastatic osteosarcoma, immunotherapy
- MeSH terms
- Animals, Bone Neoplasms, Female, Humans, T-Lymphocytes, Immunotherapy, Adoptive, Mice, Inbred NOD, Receptor, EphA2, Mice, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. https://app.cochat.ai/papers/10.1038/s41417-020-00221-4
- The paper
- Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B. (2021). Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Therapy. https://doi.org/10.1038/s41417-020-00221-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.